Exclusive Summary

• Differentiated molecular design with Best-in-Class (BIC) potential: Utilizing a unique "HSA fusion + single-arm" structure (3rd-gen IL-15), it significantly limits Cytokine Release Syndrome (CRS) risks and enables tumor-targeted enrichment compared to marketed Fc-fusion competitors.
• Superior preclinical safety window and synergistic efficacy: GLP non-human primate toxicology studies demonstrated a higher maximum non-severely toxic dose (HNSTD) than N-803, alongside powerful synergistic anti-tumor effects and enhanced immune cell infiltration when combined with BCG or targeted therapies in NMIBC and Lymphoma models.
• Inherent commercial value as an ideal "backbone" combination therapy: By robustly activating CD8+ T and NK cells and turning "cold" tumors "hot," UB676 is perfectly positioned to partner with multinational companies' existing portfolios of immune checkpoint inhibitors (ICIs), antibodies, or cell therapies.
• De-risked regulatory status and robust global IP protection: Successfully cleared for IND by both the US FDA and China CDE, backed by strong global PCT/US patent families covering molecular design, sequences, and therapeutic applications.

Asset Materials

Contact Us for Full Materials